Short answer
FATE THERAPEUTICS INC (FATE) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (down 43.4% year over year) with net income of −$32M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- −43.4% YoY · −8.7% QoQ
- Net income
- −$32M
- +32.4% YoY · +5.3% QoQ
- Operating margin
- -1995.1%
- EPS (diluted)
- −$0.27
- +32.5% YoY · +6.9% QoQ
Source: XBRL data from the FATE THERAPEUTICS INC (FATE) Q3 2025 10-Q on SEC EDGAR. USD.
FATE THERAPEUTICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $1.7M, down from $3.1M YoY
- R&D expense $25.8M vs $34.7M YoY, down $8.8M
- General and administrative expense $10.7M vs $20.8M YoY, down $10.1M
- CIRM funding received $3.8M for FT836, with $2.3M current liability and $1.5M non-current
- Outlook: continued operating losses and significant R&D investment, with unpredictable development timelines and potential supply-chain disruptions
Risk Factors
- No explicit new risk factor identified; excerpt presents broad carried-forward development risks
- Clinical development risk: all product candidates remain in research or early clinical development without regulatory approvals
- Regulatory risk: FDA may require additional studies after changes to the standard of care
- Operational risk: internal San Diego facilities produce all clinical iPSC-derived NK- and T-cell supplies
- Financial risk: manufacturing costs may exceed expectations and impair clinical-trial economics
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FATE THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.